<DOC>
	<DOCNO>NCT01742208</DOCNO>
	<brief_summary>This Phase 2 study intend assess pharmacodynamics ( PD ) , pharmacokinetics ( PK ) , safety efficacy LX4211 follow daily oral administration 29 day patient type 1 diabetes mellitus ( T1DM ) .</brief_summary>
	<brief_title>Safety Efficacy LX4211 Patients With Inadequately Controlled Type 1 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Adults ≥18 ≤55 year age Confirmed diagnosis T1DM , diagnose prior age 40 year , least 6 month prior Screening Willing refrain use carbohydrate counting adjust insulin study Willing able wear operate continuous glucose monitor Willing able selfassess bloodglucose Willing able provide write informed consent History type 2 diabetes mellitus diabetes result acromegaly , Cushing 's disease , chronic pancreatitis , pancreatectomy Two severe episode hypoglycemia require emergency treatment within 3 month prior Screening Use premixed insulin History diabetic ketoacidosis within 1 year screen Presence active hepatic disease clinically significant abnormal liver function test History chronic pancreatitis Subjects history heart attack , severe/unstable angina , coronary revascularization procedure History clinically significant cardiac arrhythmia within 1 year prior screen Subjects congestive heart failure Subjects uncontrolled Stage III hypertension History human immunodeficiency virus ( HIV ) hepatitis C History illicit drug alcohol abuse within 12 month prior Screening Use investigational agent device within 30 day prior Screening therapeutic protein antibody within 90 day prior Screening Use medication herbal supplement take weight loss within 2 week screen Chronic use antidiabetic therapy insulin within 2 month prior Screening Use systemic inhale corticosteroid within 2 week prior Screening Subjects undergone major surgery within 6 month prior Screening Inability difficulty swallow whole tablet capsule Women pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>